Patent intelligence · US
US 11285163
Ophthalmic solution
Ophthalmic solution
Patent details — US 11285163
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 29, 2022
- Expiration
- Mar 24, 2042
- Applicant
- SENTISS PHARMA PRIVATE LIMITED
- Claims
- 12
- CPC classes
- A61K, A61K2300/00, A61K31/5377, A61K31/542
Quick answer
US 11285163 (Ophthalmic solution) is held by SENTISS PHARMA PRIVATE LIMITED. Status: granted. Granted Mar 29, 2022. Expires Mar 24, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- SENTISS PHARMA PRIVATE LIMITED
- Grant date
- Expiration
- Claims
- 12
- CPC classes
- A61K, A61K2300/00, A61K31/5377, A61K31/542, A61K31/5575, A61K45/06
More from SENTISS PHARMA PRIVATE LIMITED
Related pharmaceutical patents in our USPTO index.
-
US 12419895
Methods for treating subjects with Prader-Willi syndrome
granted -
US 12350258
Compositions and methods for treatment of skin-related diseases and promoting dermatological health
granted -
US 12343348
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
granted -
US 12343381
Dosage regimen for pegylated interferon
granted -
US 12178823
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
granted -
US 12109216
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
granted -
US 12005081
Chimeric receptors and methods of use thereof
granted -
US 11884656
Pyrrole derivatives as PLK1 inhibitors
granted
Related coverage
BBSW AI Solution: Key Insights from the 2026 Event
The BBSW AI Solution event in Foster, USA, promises to unveil critical advancements in AI technology for the pharma industry. Stay tuned for live updates and key takeaways.
BBSW AI Solution 2026: Key Insights and Highlights
The BBSW AI Solution event in 2026 is set to unveil groundbreaking advancements in AI technology. Join us for live coverage and key insights from industry leaders.
Frequently asked questions
What is US patent 11285163?
US 11285163 (Ophthalmic solution) is held by SENTISS PHARMA PRIVATE LIMITED. Status: granted. Granted Mar 29, 2022. Expires Mar 24, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11285163?
SENTISS PHARMA PRIVATE LIMITED is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 95 pharmaceutical patents for this assignee.
When does US 11285163 expire?
Our index shows an expiration date of Mar 24, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.